Century Therapeutics Launches with $250M Financing for iPSC Allogeneic Cell Therapy Platform

Century Therapeutics Launches with $250M Financing for iPSC Allogeneic Cell Therapy Platform Incubated by Versant in partnership with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies. Leaps by Bayer leads investment round with $215 million commitment to develop next-generation immune oncology treatments.

01.07.2019

Century Therapeutics, a Versant Ventures-created company developing allogeneic or off-the-shelf immune cell therapies for cancer, emerged from stealth mode today with $250 million in financing commitments from Bayer, Versant and FUJIFILM Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies.

Today's announcement adds Leaps by Bayer as an integral partner in Century's investor syndicate. Leaps by Bayer, the venture investment arm of the global life sciences company Bayer, is dedicated to making paradigm-shifting advances in the life sciences.

Curing and preventing cancer is one of the main focus areas of Leaps by Bayer, since it still represents one of today's biggest health concerns with limited curative or preventative therapies available. Dr. Juergen Eckhardt, head of Leaps by Bayer, said: We are very excited about the potential of Century's platform. It represents a unique opportunity in the development of next generation cell therapies that promise to address previously incurable cancers.

Century's foundational technology is built on induced pluripotent stem cells (iPSCs) that have unlimited self-renewing capacity. This enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic, homogeneous therapeutic products. This platform differentiates Century from competitors that are developing cell therapies made from non-renewable donor-derived cells.

Century was founded in 2018 with a strategic partnership between Versant and FCDI, a subsidiary of FUJIFILM Corporation, to develop iPSC-derived immune effector cells for cancer. FCDI's vertically integrated iPSC platform has been optimized over the last 15 years to include the foremost reprograming technology that uses genome integration-free methods to generate GMP grade iPSC lines. Century also has exclusive access to FCDI's leading immune effector cell differentiation protocols and intellectual property to manufacture GMP-grade immune effector cells at commercial scale. Under the terms of the iPSC platform license agreement, FCDI will serve as the primary manufacturer of Century's cellular products.

The Versant team has tracked the cell therapy space for years and made the strategic decision to build a company focused on truly off-the-shelf products engineered for both hematologic and solid tumors, said Carlo Rizzuto, Ph.D., a Versant partner and Century director. Today's debut of Century is the culmination of our efforts to map the cell therapy space in hopes of bringing off-the-shelf products to cancer patients.

Fujifilm's mission is to bring new value to society through innovation and the creation of new technologies, products and services. We are confident that FCDI's cutting edge iPSC technologies and promising regenerative medicine solutions currently under development, can create new value to fulfill unmet medical needs and improve the lives of patients around the world, said Toshikazu Ban, Corporate Vice President of FUJIFILM Corporation. By accelerating development of new cancer immunotherapy using allogeneic iPSC through Century, we aim to deliver the therapy to patients as soon as possible.

The financial support and expertise from this consortium of partners will enable Century to realize the full potential of our iPSC platform and expand patient access to cell therapy, said Lalo Flores, Ph.D., CEO of Century. I am grateful to have their experience to guide the development of our promising allogeneic cell therapies for cancers with a high unmet need.

In addition to Dr. Flores, Century's promising technology has attracted a highly experienced team in cell therapy research and development that includes Hyam Levitsky, MD, President of Research and Development; Luis Borges, PhD., Chief Scientific Officer; and Adrienne Farid, PhD., Chief Development Officer. The company also has a pair of world renowned scientific co-founders including Marcela Maus, MD, Ph.D., assistant professor of medicine at Harvard Medical School and director of the Cellular Immunotherapy Cancer Center at Massachusetts General Hospital, and Hiro Nakauchi, MD, Ph.D., professor of genetics at Stanford University.

About Century Therapeutics Century Therapeutics is harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. Century's genetically-engineered, iPSCs-derived immune effector cell products are designed to specifically target hematologic and solid cancers. Its commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.

About Bayer and Leaps by Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Bayer's products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, Bayer aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Bayer global group employed around 117,000 people and had sales of 39.6 bi

LINK:	https://www.fujifilm.eu/uk/news/article/century-therapeutics-launches-...
	See more stories from fujifilm

Most recent headlines